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ABSTRACT 17 
A rapid and simple method for the simultaneous quantification of AFB1 and OTA in rat plasma, 18 
liver and kidney by UHPLC-FLD has been successfully validated according to the following 19 
criteria: selectivity, stability, linearity, precision, accuracy, recovery, robustness and limits of 20 
quantification and detection. The extraction method, calibration curves and chromatographic 21 
conditions are common for the three matrices. Plasma and homogenized tissue samples (100 22 
µL) were extracted with acetonitrile-formic acid mixture (99:1) (300 µL). Chromatographic 23 
separation was performed with a mixture of water and acetonitrile:methanol (50:50), both 24 
acidified with 0.5% of formic acid using a gradient profile. The method avoids the use of 25 
immunoaffinity columns and allows reduction of sample and solvent volumes as well as toxic 26 
wastes. The detection is based on a photochemical reaction which enhances the AFB1 27 
response without affecting the OTA signal before reaching the fluorescent detector. The 28 
mycotoxin recovery for each matrix was very efficient, between 93% and 96% for AFB1 and 29 
between 94% and 96% for OTA. For both mycotoxins the LOQs were 2 µg/L in plasma and 8 30 
µg/kg in liver and kidney. The method has successfully been applied to rat samples after a 31 
single oral administration of a mixture of AFB1 and OTA and it could be a useful tool in 32 
toxicokinetic and toxicological studies.  33 
KEYWORDS: Aflatoxin B1, ochratoxin A, UHPLC-FLD, validation, plasma, tissues. 34 
35 
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1. Introduction 36 
Mycotoxins are small (MW~700 amu) secondary metabolites produced by different fungal 37 
species that can contaminate many agricultural commodities during harvest and/or while in 38 
storage. Most of mycotoxins are produced by Fusarium (pre-harvest), Penicillium (post-harvest) 39 
and/or Aspergillus (pre/post harvest) fungi. They can reach human beings through 40 
contaminated food, as well as via edible products (milk, eggs, meat, blood, etc) obtained from 41 
animals fed with contaminated feeds [1]. Due to the globalization of the trade in agricultural 42 
commodities, mycotoxins may currently appear in any developed or developing country in local 43 
or imported products. 44 
Aflatoxins and ochratoxin A (OTA) belong to the most frequently occurring mycotoxins [2]. The 45 
IARC classified Aflatoxin B1 (AFB1) and OTA as class 1 (human carcinogen) and class 2B 46 
(possible human carcinogen), respectively [3, 4, 5]. Aflatoxin B1 is genotoxic in vivo and in vitro; 47 
its target organ is liver but it may cause tumors in other organs such as colon and kidney [6, 7]. 48 
Ochratoxin A is a potent nephrocarcinogenic compound in rodents but despite the controversy 49 
with regard to its mechanisms of action, some existing research suggests that it is an indirect 50 
genotoxic agent. Moreover, OTA is nephrotoxic, hepatotoxic, teratogenic and immunotoxic, and 51 
recent studies have related it to neurodegenerative diseases such as Parkinson and Alzheimer 52 
[8, 9]. Due to the aforementioned, a Tolerable Weekly Intake (TWI) of 120 ng/kg of body weight 53 
has been established for OTA [10] but, as of yet there is no threshold for AFB1; therefore, 54 
ALARA (as low as reasonably achievable) principle limit must be applied as it is not possible to 55 
identify an intake without risk [11].  56 
Human population is chronically exposed to multiple mycotoxins because of several reasons. 57 
First, the same food might be contaminated by more than one mycotoxin as the co-occurrence 58 
of AFB1 and OTA in edible products has been demonstrated; some examples are in dried fruits 59 
and figs [12], in paprika [13, 14], and in breakfast cereals [15]. Moreover, since the human diet 60 
is varied, mycotoxins might reach humans from different pathways; and, finally, mycotoxins are 61 
thermostable and can remain in food even after the fungus has been removed [1]. Co-exposure 62 
to different mycotoxins, could originate synergic or additive toxic effects on human or animal 63 
health; however, knowledge regarding this aspect or regarding the influence of co-ocurrence on 64 
toxicokinetic or toxicological characteristics of the mycotoxins is still scarce.  65 
Reference literature reports numerous methods for individual quantification of AFB1 or OTA, 66 
most of which are applied to foodstuffs, but also applied to animal matrices such as poultry [16], 67 
fish meat [17] eggs [18], milk [18, 19], swine [20], and meat and meat products[18, 19]. 68 
Nevertheless, very few of these studies are suitable for application in complex biological 69 
samples and/or during toxicological studies because they use large volumes of sample, which is 70 
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not easily available when working with laboratory animals. Moreover, most of these studies do 71 
not report validation data, which is very important so as to provide evidence of the reliability of 72 
the results [21].  73 
The development and validation of methods for the simultaneous determination of the most 74 
important mycotoxins in biological matrices would be very useful because they would be 75 
adequate tools for toxicokinetic and toxicology studies that investigate the effects of co-76 
exposure, minimizing the cost of the analysis and the use of laboratory animals.  77 
In this paper, a UHPLC-FLD method with simultaneous extraction and analytical quantification 78 
procedures for AFB1 and OTA and in rat plasma, kidney and liver has been validated and 79 
successfully applied in biological samples, demonstrating its usefulness for toxicological or 80 
toxicokinetic studies. 81 
2. Materials and methods   82 
2.1 Safety precautions 83 
Aflatoxin B1 and ochratoxin A are toxic substances. They were always manipulated in solution, 84 
avoiding the formation of dust and aerosols. Nitrile gloves were used for all procedures carried 85 
out and during the manipulation of treated animals or contaminated samples FPP3 masks were 86 
used.  87 
2.2 Reagents  88 
For the analytical standards, AFB1 was purchased as a solution of 2 mg/L in acetonitrile (ACN) 89 
and OTA was purchased as a solution of 10 mg/L in ACN, both from OEKANAL® Fluka 90 
(Schnelldorf, Germany) as certified reference materials. For oral administration, mycotoxins 91 
were purchased in powder from Sigma (Steinheim, Germany) and they were dissolved in 0.1 M 92 
NaHCO3 (Riedel-de Haën, Seelze, Germany), adjusted to pH 7.4 with HCl and maintained at -93 
20ºC until their use. For the tissue homogenates, sodium phosphate buffer (0.05 M, pH 6.50) 94 
was prepared by adding 6.90 g of NaH2PO4.H2O (Merck, Darmstadt, Germany) to 900 mL of 95 
type II water. The pH of the dissolution was adjusted to 6.5 with NaOH (Agilent technologies, 96 
Waldbronn, Germany) and the volume was adjusted to 1L. All reagents used for the HPLC 97 
analysis were of analytical grade. ACN and methanol (MeOH) HPLC grade and formic acid 98 
were obtained from Sigma Aldrich (St. Quentin Fallavier, France). Millipore type I water was 99 
obtained daily from a Milli-Q water-purifying system (Millipore, Bedford, MA, USA).  100 
2.3 Standard solutions 101 
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Working standard solutions (mixture of AFB1 and OTA) were prepared by appropriate dilution of 102 
the commercial standards with ACN and MeOH to a proportion of 50:50 v/v. Four working 103 
solutions were prepared (750, 300, 30 and 3 µg/L of AFB1 and OTA) and stored at -20ºC. The 104 
calibration standards were prepared by evaporating volumes of working standard solutions 105 
(after being kept at room temperature during 30 minutes) under a stream of nitrogen and then 106 
the residues were dissolved in 200 µL of mobile phase. The calibration standards were kept in 107 
the injection tray at 4ºC without illumination until analysis.   108 
2.4. Animals 109 
The in vivo experiments were approved by the Ethics Committee on Animal Experimentation of 110 
the University of Navarra. 111 
Ten-week-old male and female Fisher 344 (F344) rats, purchased from Harlan (Horst, The 112 
Netherlands), were used. On the day of arrival, the animals were weighed (weight variation did 113 
not exceed ± 20% [22, 23]) and then distributed to polycarbonate cages with stainless steel 114 
covers for one week in order to allow acclimatization to the environmental conditions: 12 h 115 
day/night cycle, temperature 22 ± 2ºC, relative humidity 55 ± 10%, standard diet (Harlan Iberica, 116 
Spain) and water ad libitum. 117 
Plasma, kidney and liver used as blank samples for the validation of the method were obtained 118 
from 12 non-treated animals (6 male and 6 female). In the application of the method, two male 119 
rats were administered a single dose of a mixture of AFB1 and OTA (0.5 mg/kg of AFB1 and 0.1 120 
mg/kg b.w. of OTA) by oral gavage. Samples of plasma, liver and kidney were extracted and 121 
analyzed.  122 
2.5 Sample obtaining and mycotoxin extraction procedure 123 
Sampling methods were based on those described by Vettorazi et al. (2008) for toxicokinetic 124 
studies of OTA in rat [24] with some modifications. Blood from decapitation was collected in BD 125 
(Plymouth, UK) Vacutainer tubes (5.4 mg K3E, 3 mL) and centrifuged at 1266 x g for 15 126 
minutes. The obtained plasma was aliquoted and stored at -80ºC until the extraction of 127 
mycotoxins was carried out. Liver and kidney were extracted from the animals, washed with 128 
water until the external blood was removed, and then blotted on filter paper. Pieces of each 129 
organ were cut and weighed. The medium weights of them (15-20% of relative standard 130 
deviation (RSD)) were: 1.64 g and 1.02 g of male and female livers respectively and 0.33 g and 131 
0.23 g of male and female kidneys respectively. Afterwards, they were flash-frozen in liquid 132 
nitrogen and stored at -80ºC. In order to prevent cross contamination between samples, all the 133 
dissection material was cleaned with water and rinsed with ethanol after each animal necropsy. 134 
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For mycotoxin quantification, kidney and liver were homogenized for approximately 1 minute in 135 
a round-bottom plastic tube (sterile PP-tube, from Greiner bio-one GmbH (Frickenhausen, 136 
Germany)) with 4 µL of cold sodium phosphate buffer (0.05 M, pH 6.50) per mg of tissue in a 137 
Polytron PT 3000 homogenizer with a metal rod (PT-DA 3012/2 TS Kinematic (Littau, 138 
Switzerland)). After each use, the homogenizer was cleaned with water, rinsed with ethanol and 139 
turned on until ethanol evaporation. The tissue homogenates were aliquoted (between 500 µL 140 
and 1mL) and stored for at least one day at -80ºC until the mycotoxin extraction was carried out.  141 
Before the extraction step, plasma or tissue homogenates were kept at room temperature for 30 142 
minutes and vortexed. Next, 100 µL of the sample (plasma or homogenates) was mixed with 143 
300 µL of the extractive solution (ACN - 1% HCOOH), vortexed for 2 minutes and centrifuged at 144 
6200 x g for 15 minutes at 4ºC in order to precipitate proteins. The supernatant (200 µL) was 145 
evaporated to dryness under vacuum (in a miVac DUO concentrator, Genevac (Ipswich, UK) 146 
during 15 min at 40ºC) and immediately afterwards the dry sample was resuspended in 200 µL 147 
of mobile phase and vortexed during 2 minutes. Plasma samples with expected high 148 
concentrations of OTA were diluted 1:20 in mobile phase. Dilution factor for plasma was 4 (80 in 149 
the case of high concentrated samples), and 16 for kidney and liver. The pH attained in the 150 
extraction step was approximately 2.6. Samples were filtered and placed in vials in the HPLC 151 
tray at 4ºC in darkness until injection 152 
2.6 Apparatus and chromatographic conditions 153 
UHPLC analyses were performed with an Agilent Technologies 1200 liquid chromatographic 154 
system equipped with a fluorescence detector (G1321A model) controlled by ChemStation 155 
B.03.02 software (Hewlett-Packard). Mycotoxins were separated on an Ascentis® Express C18 156 
column (150 mm x 2.1 mm; 2.7 µm) from Supelco (PA, USA). The mobile phase was a mixture 157 
of an organic phase (A) (MeOH-ACN, 50:50, v/v) and water (B), both acidified with 0.5 % of 158 
formic acid. The injection volume was 40 µL and the flow rate was 0.9 mL/min. Chromatography 159 
was performed at 60ºC. Proportion of both organic and aqueous phases was switching between 160 
isocratic and gradient profiles during the entire analysis procedure. The elution program starts 161 
isocratic until minute 2.4 with 30% of A, then from minute 2.4 to 2.5 min the organic phase 162 
increases up to 43%, from minute 2.5 to 8.3 min another isocratic profile at 43% of A, from 163 
minute 8.3 to 10.0 there is a last increase up to 65% of A and finally, from minute 10.0 the 164 
system returns to 30% of A to restore the starting conditions during 5 minutes. The retention 165 
times under these conditions were 2.5 minutes for AFB1 and 8.4 minutes for OTA. Before the 166 
sample entered the fluorescence detection cell, a photoderivatization device (AURA Industries, 167 
NY, USA) with a mercury lamp (λ = 254 nm) and a knitted reactor coil of 0.25 mL (5 m x 0.25 168 
mm) was included. During the first 4 minutes of analysis, fluorescence conditions were 169 
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optimized for AFB1 (excitation 366 nm and emission 433 nm wavelengths), and after that for 170 
OTA (excitation 225 nm and emission 461 nm wavelengths)  171 
The chromatographic separation was evaluated for each matrix at the limit of quantification level 172 
using the following parameters: retention time (tR,) retention factor (k'), symmetry, peak width at 173 
half height (wh), number of theoretical plates (N) and resolution (Rs). 174 
2.7 Validation of the UHPLC-FLD method 175 
The analytical method was validated for each mycotoxin according to the following method 176 
performance characteristics: selectivity, stability, linearity, precision and accuracy (within- and 177 
between-day variability), recovery (in intermediate precision conditions), limits of detection 178 
(LOD) and quantification (LOQ), and robustness. Selectivity, LOD, LOQ, recovery and stability 179 
were studied for each matrix. For this purpose, a pool of blank samples of plasma, kidney or 180 
liver obtained from 12 animals (6 male and 6 female) was used. 181 
Selectivity of the method was improved by using a photochemical reactor (PHRED) before a 182 
fluorescence detector with blank plasma and tissue homogenates. However, the ability of the 183 
method to distinguish AFB1 and OTA from other endogenous components was evaluated for 184 
the 3 matrices by analyzing and comparing blank samples before and after being spiked with 185 
the mycotoxins at LOQ levels. Moreover, due to the fact that OTA basal levels were detected in 186 
plasma, samples that are naturally contaminated with OTA were analyzed and afterwards 187 
spiked with a standard solution in order to see an increase of the area of the corresponding 188 
peak. In addition, in both cases (naturally contaminated and spiked) the samples were 189 
reanalyzed after changing the % of organic component in the mobile phase in order to delay 190 
OTA peak and therefore be able to observe the presence or absence of broadening, shoulders 191 
or others interfering peaks. 192 
The stability of mycotoxins was determined in the working solution, during storage of samples at 193 
-80ºC and in the chromatograph tray before analysis at 4ºC. Three concentrations of working 194 
solutions (1, 10 and 100 µg/L) stored at -20ºC were analyzed during 8 weeks. Mycotoxin 195 
stability in the HPLC chromatographic tray was evaluated for the three matrices by analyzing 196 
the extracts of spiked samples (40 µg/L plasma and 160 µg/kg liver/kidney) just after 197 
preparation and over a period of 15h. Moreover, the stability of mycotoxins in plasma and in 198 
tissue homogenates stored at -80ºC has also been determined by analyzing spiked samples (40 199 
µg/L plasma and 160 µg/kg liver/kidney) 24h, 1 week, 1 month and 6 months after preparation.  200 
For each mycotoxin, two calibration curves were plotted from 0.5 up to 150 µg/L using 201 
calibration standards. The range was split into two: a low calibration curve from 0.5 to 30 µg/L, 202 
with eight data points; and a high calibration curve from 30 to 150 µg/L with six data points. 203 
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Three replicates of each calibration standard were analyzed. Within- and between-day precision 204 
and accuracy of the linearity were studied by analyzing three replicate calibrations standards at 205 
0.5, 2, 15, 30, 90 and 150 µg/L on one day (within-day) and on three different days (between-206 
day).  207 
Due to the fact that adequate reference biological spiked materials were not available, 208 
fortification was carried out with known concentrations of mycotoxins in order to establish the 209 
recovery and precision of the method. AFB1 and OTA were added to blank plasma, liver or 210 
kidney homogenate pools in order to obtain 2, 8, 120, 600 µg/L in plasma, and 8, 32, 480, 2400 211 
µg/kg in organs, in triplicate. The corresponding volume of the working standard was 212 
evaporated under a stream of nitrogen and resuspended in 100 µL of blank plasma, kidney or 213 
liver homogenate by mixing in vortex for 2 min. Mycotoxins were then extracted as described in 214 
section 2.4 and then analyzed. In order to assure the quantification of very high levels of OTA 215 
(levels in plasma higher than 600 µg/L could be expected), a dilution step was added when 216 
analyzing the recovery of 600 µg/L. Just after resuspending the plasma fortification extract in 217 
mobile phase (200 µL), 10 µL of this suspension were added to 190 µL of mobile phase, mixed 218 
and analyzed. The dilution factor was 20; therefore, it was possible to cover a range of up to 219 
6000 µg/L in plasma. The recovery values (%) for all of the matrices were calculated by dividing 220 
the experimental mycotoxin concentration obtained by the nominal mycotoxin level. In the 221 
spiked plasma samples, the response was subtracted from the areas obtained in the plasma 222 
blank pool. The repeatability and intermediate precision of this process were studied by carrying 223 
out the complete recovery experiment for each matrix, for the 4 concentrations on one day and 224 
on three different days.  225 
LOQ was determined by analyzing three replicates of fortified plasma (2, 4, 8 µg/L), kidney and 226 
liver (8, 16, 32 µg/kg). The lowest concentration for which acceptable data of recovery and 227 
precision was obtained was considered to be the LOQ [25].  228 
LOD was calculated theoretically using the method based on the calibration curve extrapolation 229 
at zero concentration [25]:  230 
LOD = [Ybl + (k x Sbl)] / b  (k=3) 231 
where Ybl and b are the intercept and the slope, respectively, of a curve that represents the area 232 
of each concentration versus the nominal concentration after analyzing the samples of spiked 233 
plasma, kidney or liver for obtaining the LOQ; k is 3; Sbl (standard deviation of the blank) is the 234 
intercept of the curve obtained by representing the standard deviation for each concentration 235 
level versus the nominal concentration.  236 
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Robustness: The influence of changes in the pH of the mobile phase (0.1% of formic acid in the 237 
aqueous phase), changes in the column batches (either new or in use), and the influence of 238 
column temperature (59ºC and 57ºC) on areas and retention times of a working standard of 30 239 
µg/L of AFB1 and OTA were studied. Moreover, it was considered to be important to study the 240 
influence of light degradation of AFB1 during sample or standard manipulation (either in 241 
darkness or exposed to light). Three replicates of the working standard were analyzed in each 242 
condition and the concentrations obtained were compared with the nominal values (30 µg/L).  243 
The acceptance/rejection criterion used were:  244 
- Stability:peak areas ± 10% of the peak areas obtained just after sample preparation (0 245 
h). 246 
- Linearity: the determination coefficient (r2) higher than 0.990, the slope interval not 247 
having to include zero (p≤0.05) and the intercept interval having to include zero (p≤0.05), 248 
the representation of residuals versus the estimated values having to rise to a 249 
distribution of the points at random and not having to reflect any trend, and the RSD 250 
(relative standard deviation) between response factors lower than 10%. ± 10% RSD and 251 
±10% standard error of the mean (SE) for all the concentrations excepting the lower one, 252 
which is the limit of quantification, and whose accepted accuracy and precision was 253 
within ±15%.  254 
- Recovery: ± 10% RSD  in repeatability and intermediate precision conditions.  255 
- Robustness: ±10% of standard error of the mean (SE) 256 
3. Results and discussion 257 
Up to now, many OTA determination studies have been performed on different biological 258 
samples and animal species using a wide variety of techniques [8, 24, 26, 27, 28, 29]. However, 259 
there is a lack of modern techniques (LC/MS and HPLC) for studying the presence of AFB1 in 260 
body fluids or tissues, and most of the methods were initially limited to their use in food matrices 261 
[18, 30], although later they were modified for their application to toxicological studies. 262 
Moreover, no validated UHPLC-FLD methods for simultaneous determination of OTA and AFB1 263 
in plasma, kidney and liver have been previously described in laboratory animals, in spite of the 264 
fact that these methods would be of great interest for toxicological or toxicokinetic studies of 265 
mycotoxins.  266 
3.1 Sample obtaining and mycotoxin extraction and cleanup. 267 
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For aflatoxins determination, chromatographic methods described by Siraj et al. (1981) [31], 268 
Gregory (1982) [32], Lamplugh (1983) [33] [34] were not suitable for toxicological studies 269 
conducted with small animals. Coulombe and Sharma (1985) [35] and Wong (1981) [36], 270 
among others, used radioactivity quantification methods in order to achieve enough sensitivity 271 
and recovery for the tiny samples that are generated during toxicological studies. Plakas et al 272 
(1991) combined an HPLC quantification with 14C-labeled AFB1 detection [37]. In the case of 273 
OTA. Vettorazzi et al [24] validated a method successfully applied in a study of OTA 274 
toxicokinetics in rats [28].  275 
The sampling method has been inspired in the work described by Vettorazzi et al. [24] for 276 
detecting OTA in plasma, liver and kidney of rats. OTA was extracted from the matrix with an 277 
organic solvent (ethanol) in very acid conditions using trichloroacetic acid (TCA). Unfortunately, 278 
this extraction process was not suitable for the simultaneous extraction of AFB1 and OTA 279 
because the pH conditions were too low for the AFB1 stability and because TCA, a trihaloacetic 280 
acid such as TFA (used for AFB1 derivatization [32, 38]), gives undesired chemical reactions. 281 
On the other hand, mycotoxins bind proteins [7, 8, 39] and the extraction step needs low pH 282 
conditions to release OTA and AFB1 and to precipitate the proteins [19]. In addition, ACN 283 
obtained clearer extracts than ethanol in preliminary studies. Therefore, proteins from samples 284 
were precipitated with acidified ACN (1:3 ratio). Combinations of ACN-HCOOH (10%, pH= 2.62 285 
and 1%, pH=2.63), ACN-H3PO4 (1%, pH=2.72 and 0.5%, pH=2.84) and ACN-HCl (0.05%, pH= 286 
2.59) were assayed. After analysis of the resulting extracts, ACN-HCOOH 1% yielded clean 287 
enough extracts and recovery values over 90% for both mycotoxins in the three matrices.  288 
With the procedure described, the simultaneous extraction of both mycotoxins has been 289 
achieved only starting from 100 µL of plasma or 25 mg of tissue and covering a range of 2-6000 290 
µg/L in rat plasma and 8-2400 µg/L in rat kidney and liver. Only one solvent step extraction is 291 
needed, avoiding immunoaffinity column clean up and toxic solvents such as chloroform, ethyl 292 
acetate or dichloromethane which cause health and environmental hazards.  293 
3.2 Development of the UHPLC-FLD quantitative analytical method 294 
Chromatographic conditions were investigated in order to achieve the best separation and 295 
resolution of peaks so as to allow quantification. The method starts with an isocratic set which 296 
permits the elution of the polar components extracted with the mycotoxins. Due to its polar 297 
properties, AFB1 appears early in the chromatogram. The front peaks corresponding to liver 298 
and kidney matrices are larger than those corresponding to plasma (figure 1). OTA needs an 299 
increase in the organic proportion of the eluent and it had to be delayed for up to minute 8.4 300 
because several interfering peaks appear in kidney and liver, something that does not occur 301 
with plasma samples.  302 
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Aflatoxin B1 and ochratoxin A have fluorescent properties that make them good candidates for 303 
their detection with the use of fluorescence. However, it is well known than AFB1 suffers 304 
quenching in aqueous solvents; therefore, derivatization reactions would be necessary to 305 
quantify low levels. Either pre-column or post-column derivatization could be possible [38, 40, 306 
41]. Pre-column derivatization was initially discarded in order to obtain a simple and quick 307 
method. In addition, post-column iodine or bromine (Kobra cell) derivatization was also 308 
discarded because both reagents need to add extra pumps and chemical reactors to the 309 
UHPLC system. Furthermore, iodine derivatization decreases OTA peak intensity [38]. The 310 
derivatization was performed with a photo-chemical reactor made with a knitted coil and a 311 
mercury lamp placed in line just after the column [41]. The PHRED makes derivatization fast 312 
and easy, and minimizes intervention of the analyst. The AFB1 signal is approximately 15 times 313 
more intense with the lamp on while OTA response remains unaffected.  314 
Due to the fact that the same method has been applied for two mycotoxins in three different 315 
matrices, the effect of possible interferences of the matrix at the limit of quantification level has 316 
been studied for each one of them. There were no substantial differences in the 317 
chromatographic parameters for the same mycotoxin in the three matrices (see table 1). 318 
3.3 Validation of the method   319 
The method was selective for kidney and liver because no interference peaks appeared at the 320 
retention time of AFB1 or OTA in blank samples. In the case of plasma, no interference peaks 321 
appeared at the retention time of AFB1; however, basal OTA levels were detected in blank 322 
plasma. The experiments made in order to assure selectivity for OTA (reanalysis of spiked blank 323 
contaminated plasma in different chromatographic conditions) showed that the standard OTA 324 
peak appeared at the same retention time as that of the interference. Moreover, after delaying 325 
of the peak, no broadening or distortion of the peak shapes was observed. 326 
The working solutions remained stable up to 4 weeks at -20ºC (results not shown). After 6 327 
weeks, the AFB1 concentration was unstable; after 8 weeks, the OTA concentration became 328 
unstable. Moreover, after 12 weeks, AFB1 started degrading in the working solution solvent 329 
(MeOH:ACN) while OTA remained unaffected. Spiked samples remained stable stored at -80ºC 330 
during 6 months (results not shown). This coincides with the stability observed for OTA in 331 
biological samples by Vettorazzi et al [24]. OTA and AFB1 were stable in processed plasma, 332 
liver and kidney for 15h in the HPLC tray at 4ºC without light (results not shown) 333 
Linearity has been assessed in a wide range of concentrations in order to include not only high 334 
levels but also levels due to natural exposures that occur in laboratory animals fed with 335 
contaminated feed [24, 26]. The four calibration curves generated showed a good linear 336 
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relationship between response (area of the peaks) and the respective AFB1 or OTA 337 
concentrations. All of the requirements for linearity have been met for the two concentration 338 
intervals of each mycotoxin (see table 2). Precision (RSD) and accuracy (SE) of the linearity 339 
showed adequate values, less than 10% in the whole interval (at the LOQ level less than 15%) 340 
(see table 3). 341 
The recovery for each matrix was very efficient, between 93% and 96% for AFB1 and between 342 
94% and 96% for OTA. Moreover, the RSDs obtained in the within-day and between-day 343 
experiments were below 10% in each case (at the LOQ level below 15%), thereby 344 
demonstrating the precision of the analytical procedure (see table 4). The range of the recovery 345 
study went up to 600 µg/L in plasma, liver and kidney; however, according to Vettorazzi et al. 346 
[24], higher concentrations of OTA might be expected in plasma, so the recovery of the dilution 347 
step was evaluated and the RSD was also below 10%. The recovery obtained in this method for 348 
AFB1 was successful for every matrix and higher than in other HPLC methods found in the 349 
literature [31, 33, 34]. In terms of OTA, the recovery was comparable to other methods for its 350 
analysis in plasma or serum, [24, 27] or higher in liver and kidney [20, 24, 27]. 351 
For both mycotoxins, the LOQs were 2 µg/L in plasma and 8 µg/kg in liver and kidney and they 352 
were considered to be the lowest concentrations in their range of quantification [21, 42]. The 353 
limits of quantification obtained for AFB1 using the photoderivatization instrument were 354 
satisfactory and better than others found in bibliography for HPLC methods [16, 32, 33, 34]. 355 
They were also comparable with radioactivity detection that uses very small amounts of sample 356 
[35, 36, 37, 43]. For OTA, quantification limits are comparable to or better than those of other 357 
HPLC methods that use 2-100 times more sample volume [19, 20, 24]. The calculated LODs for 358 
AFB1 were as follows: 0.1 µg/L in plasma and 0.01 µg/kg in kidney and liver; the calculated 359 
LODs for OTA were: 0.3 µg/L in plasma and 0.01 µg/kg in kidney and liver.  360 
In the study of robustness (see table 5), the pH of the mobile phase had a significant impact on 361 
the quantification of OTA. An increase in the pH yielded a decrease in the OTA signal, whereas 362 
AFB1 signal remains without changes. Ochratoxin A has been described as a weak acid and it 363 
is important to maintain a pH below 4.4 in order to assure that OTA molecule is in its protonated 364 
form [19]. In addition, different lots of columns were tested and the quantification was 365 
satisfactory while the retention times appeared to be affected. On the other hand, peak areas 366 
did not change after slight differences in column temperature. Due to the high pressure 367 
conditions of the chromatography, slight changes in temperature, column batches or flow 368 
affected the pressure; as a result, the retention times were affected but the quantification was 369 
considered to be robust. Moreover, it was very important to keep samples in the dark during 370 
their obtainment or manipulation due to the fact that AFB1 degrades easily when exposed to 371 
light.  372 
13 
3.4 Application to real samples 373 
The method was successfully applied in real samples obtained from rats that received 374 
administration of a mixture of AFB1 and OTA (0.5 mg/kg b.w.) in a single dose by oral gavage 375 
(see table 6). The analytical results have been corrected with the recovery value for each 376 
mycotoxin. The highest level found in plasma for OTA was 919 µg/L, the dilution step (d=20) 377 
was applied and permitted quantification. On the contrary, low levels of AFB1 have been 378 
detected in plasma samples (<LOD). In kidney and liver, comparable levels of OTA have been 379 
found in both organs, and AFB1 was at a very low level in both of them. 380 
4. Conclusions 381 
A rapid and simple method for the simultaneous quantification of AFB1 and OTA in rat plasma, 382 
liver and kidney by UHPLC-FLD has been validated and successfully applied. The process is 383 
economical because only low volumes of solvents are needed, and the use of immunoaffinity 384 
columns is not necessary in the purification process. In addition, this method uses a low-volume 385 
column that permits working under high pressure conditions, thereby giving high resolution in 386 
short time assays. The two most important advantages of this method are that it enables the 387 
simultaneous quantification of AFB1 and OTA in three biological matrices, and that only 100 µL 388 
of plasma or 25 mg of tissue are sufficient enough for obtaining results in a wide range of 389 
concentrations, with adequate recovery and LOD and LOQ values. These characteristics make 390 
it very useful for carrying out experimental work in toxicokinetic and toxicological studies.  391 
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Captions to illustrations: 461 
Figure 1: Superimposed chromatograms of blank, spiked and post-administration extracted 462 
sample of A) plasma, B) liver and C) kidney. 463 
464 
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Table 1: Table 1: Chromatography parameters of AFB1 and OTA obtained at the concentration 466 
of the limit of quantification in plasma, liver or kidney.  467 
    AFB1   OTA 
    Plasma Liver Kidney   Plasma Liver Kidney 
Retention time (tR) (min) 2.54 2.59 2.58   8.38 8.50 8.48 
Retention factor (k') 2.45 2.95 3.05   10.38 11.97 12.29 
Symmetry 0.77 0.78 0.65   0.94 1.09 0.97 
Peak width at half height (wh) 0.13 0.13 0.14   0.11 0.12 0.11 
Number of theoretical plates (N) 2099 2115 1935   29631 28867 31130 
Resolution (Rs)* 3.11 7.61 9.26   21.41 20.58 20.58 
* Calculated between the mycotoxin peak and its nearest peak in the chromatogram468 
20 
Table 2: Linearity data calculated with three replicates of each concentration of the range.  469 
Mycotoxin
Range  
Curve equation 
y=(b±Sb)x+(a±Sa)* 
Determination 
coefficient (r2) Slope limits Intercept limits 
RSD(%) 
response 
factor 
Standard 
(µg/L) 
Plasma 
(µg/L) 
Liver/Kidney  
(µg/kg) 
AFB1 
0.5-30 2-120 8-480 y=(2.11 ± 0.03)x+(0.06 ± 0.43) 0.9988 (2.04; 2.18) (-0.99; 1.10) 2.5 
30-150 120-600 480-2400 y=(2.48 ± 0.06  )x-(7.78 ± 5.74) 0.9975 (2.31; 2.65) (-23.72; 8.15) 6.1 
OTA 
0.5-30 2-120 8-480 y=(2.52 ± 0.03) x+(0.19 ± 0.49) 0.9989 (2.43; 2.60) (-1.01; 1.38) 3.5 
30-150 120-600 480-2400 y=(2.90 ± 0.09)x-(7.45 ± 7.96) 0.9965 (2.66; 3.14) (-29.56; 14.66) 6.3 
*: b: slope, Sb standard deviation of the slope, a: intercept, Sa: standard deviation of the intercept470 
21 
Table 3: Precision and accuracy of the instrumental system 471 
Mycotoxin Concentration (µg/L) 
  Repeatability (within-day) (n=3)  Intermediate precision (between-day) (n=9)
  Mean RSD (%) SE (%)  Mean RSD (%) SE (%) 
AFB1 
0.5   0.44 7.3 13.0  0.44 5.6 12.2 
2   2.1 4.1 5.3  2.0 5.7 1.0 
15   14.9 4.0 0.3  16.1 5.9 7.2 
30   31.7 6.4 5.8  30.0 6.0 0.0 
90   84.7 8.6 5.8  88.9 6.5 1.1 
150   147 2.1 1.7  153 3.8 2.4 
OTA 
0.5   0.45 8.6 9.9  0.45 7.8 10.8 
2   2.0 2.8 0.6  2.2 6.5 9.2 
15   14.5 3.5 3.6  15.7 6.3 4.6 
30   31.1 6.3 3.7  29.6 5.9 1.2 
90   87.1 8.3 3.2  91.2 6.9 1.4 
150   153 2.0 2.1  158 3.4 5.6 
 472 
 473 
22 
Table 4: Recovery study for AFB1 and OTA in plasma, liver and kidney 474 
Mycotoxin   Concentration (µg/L)a (µg/kg)b 
 Repeatability (within-day)  Intermediate precision (between-day) 
 Recovery (%) 
n=3 
RSD (%) 
n=3 
Global 
recovery (%) 
n=12 
RSD (%) 
n=12 
 Recovery (%) 
n=9 
RSD (%) 
n=9 
Global 
recovery (%) 
n=36 
RSD (%) 
n=36   
AFB1 
Plasma
2  89.1 1.5  
 
93.8 
  
 
 
5.7 
  
 85.4 4.1  
 
93.0 
  
 
 
8.9 
  
8  95.1 2.6  97.1 5.5 
120  101.5 1.6  102.9 2.1 
600  89.7 1.0  86.7 5.0 
(d=20)* 30  99.0 5.5  103.4 6.6 
Liver 
8  97.9 4.1 
95.8 6.0 
 92.2 10.4 
95.2 8.1 32  94.8 2.5  97.8 5.2 480  101.9 2.9  102.5 2.3 
2400  88.6 2.9  88.2 2.7 
Kidney 
8  94.2 3.3 
97.0 5.8 
 100.7 6.2 
96.0 8.1 32  102.0 1.9  94.3 9.7 480  101.0 2.3  100.0 3.1 
2400  91.2 6.5  88.7 5.4 
OTA 
Plasma
2  97.9 1.5  
 
96.5 
  
 
 
7.5 
  
 92.8 5.8  
 
96.0 
  
 
 
8.9 
  
8  88.3 3.6  91.5 5.6 
120  106.6 1.9  108.7 2,1 
600  93.1 0.8  91.2 4.8 
(d=20)* 30  96.1 5.8  103.2 7.9 
Liver 
8  82.5 4.9 
91.3 10.0 
 90.3 8.7 
94.4 8.8 32  89.5 4.5  89.7 5.4 480  105.4 3.0  105.9 2.4 
2400  90.3 2.8  91.5 2.8 
Kidney 
8  91.4 4.9 
96.9 7.1 
 85.1 8.5 
94.5 9.7 32  95.4 5.7  91.6 5.6 480  105.6 2.0  106.1 2.5 
2400  95.1 6.6  95.3 4.4 
        
a :µg/L for plasma, b :µg/kg for liver and kidney                
*: recovery study of the dilution step (d=20) of plasma                
475 
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Table 5: Study of robustness with standards: % of HCOOH in mobile phase, different column batches, changes in column temperatures and 476 
exposure to light.  477 
           AFB1   OTA 
       Concentration (µg/L)  Retention time (min)   Concentration (µg/L)  Retention time(min) 
       Mean SE (%)  Mean SE (%)   Mean SE (%)  Mean SE (%) 
Nominal  30    2.55     30    8.43   
0.1% HCOOH in mobile phase  30.0 0.0  2.53 0.7  25.7 14.2  8.33 1.1 
Column batch A  29.4 2.0  2.21 13.0  30.6 2.0  7.48 11.3 
Column batch B  27.7 7.5  2.38 6.3  30.6 1.9  7.81 7.3 
Column at 59 ºC  29.0 3.2  2.55 0.0  30.0 0.1  8.33 1.2 
Column at 57 ºC  29.3 2.2  2.65 4.1  30.1 0.3  8.69 3.1 
Day light exposure  degraded  28.7 4.5  8.38 0.6 
24 
Table 6: Concentration of AFB1 and OTA in plasma (µg/L), liver and kidney (µg/kg) from rats 478 
administered AFB1+OTA (0.5 mg/kg b.w.) by oral gavage.  479 
      Concentration (µg/L)a (µg/kg)b
  Sample  AFB1 OTA 
Plasma 
1  9.8 427 
2  3.1 919 
3  0.13c 543 
4  <LOD 528 
5  1.7c 549 
6  <LOD 422 
7  <LOD 424 
8  <LOD 420 
Liver 
1  <LOD 35.5 
2  <LOD 31.7 
Kidney 
1  6.1c 42.6 
2  6.6c 41.5 
 
a :µg/L for plasma, b :µg/kg for liver and kidney 
c :<LOQ 
 480 
 481 
